Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Hum Reprod ; 23(8): 1808-14, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18480088

RESUMEN

BACKGROUND: In modified natural cycle IVF (MNC-IVF), treatment is aimed at using the one follicle that spontaneously develops to dominance, using a GnRH-antagonist together with gonadotrophins in the late follicular phase only. The MNC-IVF is of interest because of its low-risk and patient-friendly profile. The effect of application of MNC-IVF preceding standard IVF with ovarian stimulation on overall results is unknown. METHODS: This single-center cohort study provides follow-up of an earlier study in which nine cycles of MNC-IVF were offered to 268 patients. Ongoing pregnancy rates and live birth rates, as well as time-to-pregnancy after controlled ovarian stimulation-IVF (COS-IVF) following MNC-IVF, were evaluated. RESULTS: Actual observed cumulative ongoing pregnancy rates and live birth rates after sequential treatment with MNC-IVF followed by COS-IVF were 51.5 (95% CI: 45.4-57.6) and 50.0% (95% CI: 43.9-56.1) per patient, of which 8.0 and 6.7% were twins. Median time to ongoing pregnancy was 28.8 weeks. Including treatment-independent pregnancies, cumulative ongoing pregnancy rate was 56.7% (95% CI: 50.7-62.8). CONCLUSIONS: Sequential treatment with MNC-IVF followed by COS-IVF does not appear to compromise overall success rates, while twin pregnancy rate is low. Because of its patient-friendly and low-risk profile, it seems appropriate to perform MNC-IVF preceding COS-IVF.


Asunto(s)
Fertilización In Vitro/métodos , Inducción de la Ovulación/métodos , Índice de Embarazo , Adulto , Peso al Nacer , Estudios de Cohortes , Femenino , Fertilización In Vitro/estadística & datos numéricos , Hormona Folículo Estimulante Humana/uso terapéutico , Hormona Liberadora de Gonadotropina/análogos & derivados , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Hormona Liberadora de Gonadotropina/uso terapéutico , Humanos , Recién Nacido , Infertilidad Femenina/terapia , Inducción de la Ovulación/estadística & datos numéricos , Embarazo , Embarazo Múltiple , Gemelos
2.
Hum Reprod ; 22(9): 2463-70, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17586833

RESUMEN

BACKGROUND: In modified natural cycle IVF (MNV-IVF), treatment is aimed at using the one follicle that spontaneously develops to dominance, using a GnRH antagonist together with gonadotrophins in the late follicular phase only. METHODS: In this single-centre cohort study, nine cycles of MNV-IVF were offered to 268 patients. Cumulative pregnancy rates (CPRs) were calculated and drop-out was analysed. The present study is an extension of earlier studies in which three cycles of MNV-IVF were offered to the same patients. RESULTS: A total of 256 patients completed 1048 cycles (4.1 per patient). Embryo transfer rate was 36.5% per started cycle. Ongoing pregnancy rate was 7.9% per started cycle and 20.7% per embryo transfer. Including treatment-independent pregnancies, the observed CPR after up to nine cycles was 44.4% (95% confidence interval 38.3-50.5) per patient. Pregnancy rates per started cycle did not decline in higher cycle numbers (overall 9.9%). Drop-out rates were high (overall 47.8%). We found that cancellation of oocyte retrieval, fertilization failure and failure to reach embryo transfer are repeating phenomena in subsequent cycles and furthermore that these events predispose for drop-out. CONCLUSIONS: CPR after nine cycles of MNV-IVF in this study was 44.4%. Pregnancy rate per cycle did not decline in higher cycle numbers, possibly due to selective drop-out of poor prognosis patients. Due to the low-risk and patient-friendly nature of the MNC protocol, it seems a feasible treatment option for patients requiring IVF.


Asunto(s)
Fertilización In Vitro/métodos , Infertilidad Femenina/terapia , Pacientes Desistentes del Tratamiento , Índice de Embarazo , Adulto , Estudios de Cohortes , Transferencia de Embrión , Femenino , Humanos , Países Bajos , Embarazo
3.
Hum Reprod ; 21(9): 2375-83, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16751647

RESUMEN

BACKGROUND: In minimal stimulation IVF, treatment is aimed at using the single oocyte that spontaneously develops to dominance. To prevent untimely ovulation, a GnRH antagonist is administered in the late follicular phase of the natural cycle together with recombinant FSH for substitution. Owing to the lack of ovarian stimulation, minimal stimulation IVF is a low-risk and patient-friendly treatment. In this study, effectiveness of minimal stimulation IVF was studied. METHODS: In this prospective multicentre cohort study, minimal stimulation IVF was offered to 350 patients. All indications for conventional IVF were included. Main outcome measures were pregnancy rates per cycle and cumulative pregnancy rates after three cycles. RESULTS: A total of 336 patients completed 844 cycles (2.5 per patient). The overall ongoing pregnancy rate per started cycle was 8.3% [95% confidence interval (CI) 6.4-10.2%]. The cumulative ongoing pregnancy rate after up to three cycles was 20.8% (95% CI 16.4-25.3%) per patient. No differences were found according to indication for IVF. CONCLUSIONS: Minimal stimulation IVF seems suitable for all indications studied. Pregnancy rates are encouraging. Owing to the low-risk and patient-friendly nature of this protocol, it seems a feasible treatment option for patients requiring IVF.


Asunto(s)
Fertilización In Vitro/métodos , Infertilidad/diagnóstico , Infertilidad/terapia , Inducción de la Ovulación/métodos , Adulto , Estudios de Cohortes , Transferencia de Embrión , Femenino , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Humanos , Oocitos/metabolismo , Embarazo , Resultado del Embarazo , Índice de Embarazo , Resultado del Tratamiento
5.
Urology ; 65(1): 196-201, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15667903

RESUMEN

OBJECTIVES: To investigate the frequency of azoospermia factor (AZF) deletions in Dutch patients with testicular germ cell tumors (TGCTs). Reduced fertility is associated with TGCTs and reduced fertility and TGCTs might share genetic risk factors according to the testicular dysgenesis hypothesis. Up to 8% of infertility and reduced fertility in the general male population can be explained by the presence of constitutional deletions of part of the long arm of the Y chromosome (Yq11), referred to as the AZF region. METHODS: In 112 patients with TGCT, screening for constitutional deletions in the AZF region was performed by multiplex polymerase chain reaction analysis in DNA extracted from peripheral blood lymphocytes. A set of 24 primer pairs, of which 20 primer pairs are homologous to previously identified and mapped sequenced tag sites within the AZF region were used. RESULTS: No deletions in the Yq11 region were detected in any of the 112 patients. CONCLUSIONS: Large Y chromosome microdeletions in the AZF region are not a major contributor to the development of TGCT and TGCT-associated reduced fertility.


Asunto(s)
Deleción Cromosómica , Cromosomas Humanos Y/ultraestructura , Germinoma/genética , Infertilidad Masculina/etiología , Proteínas de Plasma Seminal/genética , Neoplasias Testiculares/genética , Criptorquidismo/genética , Análisis Mutacional de ADN , Sitios Genéticos , Germinoma/complicaciones , Humanos , Infertilidad Masculina/genética , Linfocitos/química , Masculino , Oligospermia/etiología , Oligospermia/genética , Reacción en Cadena de la Polimerasa , Seminoma/complicaciones , Seminoma/genética , Neoplasias Testiculares/complicaciones
6.
Hum Reprod ; 20(3): 642-8, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15608031

RESUMEN

BACKGROUND: The use of the natural cycle for IVF offers the advantage of a patient-friendly and low-risk protocol. Its effectiveness is limited, but may be improved by using a GnRH antagonist to prevent untimely LH surges. METHODS: In this pilot study, minimal stimulation IVF with late follicular phase administration of the GnRH antagonist cetrorelix and simultaneous substitution with recombinant FSH was applied for a maximum of three cycles per patient. Main outcome measures were pregnancy rates per started cycle and cumulative pregnancy rates after three cycles. RESULTS: A total of 50 patients completed 119 cycles (2.4 per patient). Fifty-two embryo transfers resulted in 17 ongoing pregnancies [14.3% per started cycle; 32.7% per embryo transfer; 95% confidence interval (CI) 7.9-20.7% and 19.7-45.7%, respectively]. One dizygotic twin pregnancy occurred after transfer of two embryos, the other pregnancies were singletons. The cumulative ongoing pregnancy rate after three cycles was 34% (95% CI 20.6-47.4%). Live birth rate was 32% per patient (95% CI 18.8-45.2%). CONCLUSIONS: Pregnancy rates after IVF with minimal, late follicular phase stimulation are encouraging. Considering the low-risk and patient-friendly nature of this protocol, it may be a feasible alternative to IVF with ovarian hyperstimulation.


Asunto(s)
Fertilización In Vitro , Hormona Folículo Estimulante/uso terapéutico , Fase Folicular , Hormona Liberadora de Gonadotropina/análogos & derivados , Hormona Liberadora de Gonadotropina/administración & dosificación , Antagonistas de Hormonas/administración & dosificación , Inducción de la Ovulación/métodos , Adulto , Esquema de Medicación , Transferencia de Embrión , Femenino , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Hormona Liberadora de Gonadotropina/uso terapéutico , Antagonistas de Hormonas/uso terapéutico , Humanos , Proyectos Piloto , Embarazo , Índice de Embarazo , Embarazo Múltiple , Proteínas Recombinantes/uso terapéutico , Gemelos Dicigóticos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA